A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease
ABSTRACT Off‐label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off‐label therapies in the pediatric IBD population. Real‐world use of ustekinumab (UST), vedolizumab (VDZ), upa...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Pediatric Discovery |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pdi3.70011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431551326027776 |
|---|---|
| author | Yassin EL‐Najjar Mary‐Joe Touma Shuai Tan Xiaoqin Zhou Qi Liu |
| author_facet | Yassin EL‐Najjar Mary‐Joe Touma Shuai Tan Xiaoqin Zhou Qi Liu |
| author_sort | Yassin EL‐Najjar |
| collection | DOAJ |
| description | ABSTRACT Off‐label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off‐label therapies in the pediatric IBD population. Real‐world use of ustekinumab (UST), vedolizumab (VDZ), upadacitinib (UPA), tofacitinib, and ozanimod in the adult population could prove positive outcomes in the pediatric population. Established off‐label therapies inch closer to comparable safety, efficacy, and outcomes in pediatric IBD use. Outcomes and use of newer biologic therapies in patients with pediatric IBD have improved with increased rates of steroid‐free clinical remission (SFCR). Novel therapies, including Janus kinase (JAK) inhibitors and sphingosine‐1‐phosphate receptor (S1Pr) modulators, require further studies but could also prove effective. |
| format | Article |
| id | doaj-art-9bd8fd593a3a4b6fbc27bb1e27bc23a9 |
| institution | Kabale University |
| issn | 2835-558X 2835-5598 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pediatric Discovery |
| spelling | doaj-art-9bd8fd593a3a4b6fbc27bb1e27bc23a92025-08-20T03:27:36ZengWileyPediatric Discovery2835-558X2835-55982025-06-0132n/an/a10.1002/pdi3.70011A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel DiseaseYassin EL‐Najjar0Mary‐Joe Touma1Shuai Tan2Xiaoqin Zhou3Qi Liu4Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USADepartment of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USADepartment of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USADepartment of Gastroenterology Children's Hospital of Chongqing Medical University National Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders China International Science and Technology Cooperation Base of Child Development and Critical Disorders Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity Chongqing ChinaDepartment of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USAABSTRACT Off‐label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off‐label therapies in the pediatric IBD population. Real‐world use of ustekinumab (UST), vedolizumab (VDZ), upadacitinib (UPA), tofacitinib, and ozanimod in the adult population could prove positive outcomes in the pediatric population. Established off‐label therapies inch closer to comparable safety, efficacy, and outcomes in pediatric IBD use. Outcomes and use of newer biologic therapies in patients with pediatric IBD have improved with increased rates of steroid‐free clinical remission (SFCR). Novel therapies, including Janus kinase (JAK) inhibitors and sphingosine‐1‐phosphate receptor (S1Pr) modulators, require further studies but could also prove effective.https://doi.org/10.1002/pdi3.70011biologic therapyCrohn’s disease (CD)pediatric inflammatory bowel disease small moleculeulcerative colitis (UC) |
| spellingShingle | Yassin EL‐Najjar Mary‐Joe Touma Shuai Tan Xiaoqin Zhou Qi Liu A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease Pediatric Discovery biologic therapy Crohn’s disease (CD) pediatric inflammatory bowel disease small molecule ulcerative colitis (UC) |
| title | A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease |
| title_full | A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease |
| title_fullStr | A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease |
| title_full_unstemmed | A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease |
| title_short | A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease |
| title_sort | review of the current state of off label therapies for pediatric inflammatory bowel disease |
| topic | biologic therapy Crohn’s disease (CD) pediatric inflammatory bowel disease small molecule ulcerative colitis (UC) |
| url | https://doi.org/10.1002/pdi3.70011 |
| work_keys_str_mv | AT yassinelnajjar areviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT maryjoetouma areviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT shuaitan areviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT xiaoqinzhou areviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT qiliu areviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT yassinelnajjar reviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT maryjoetouma reviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT shuaitan reviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT xiaoqinzhou reviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease AT qiliu reviewofthecurrentstateofofflabeltherapiesforpediatricinflammatoryboweldisease |